RestorGenex Corp. Stock Price, News & Analysis (NASDAQ:DFFN)

$1.35 0.02 (1.50 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$1.35
Today's Range$1.44 - $1.31
52-Week Range$1.27 - $15.50
Volume88,336 shs
Average Volume318,947 shs
Market Capitalization$19.49 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.94

About RestorGenex Corp. (NASDAQ:DFFN)

RestorGenex Corp. logoDiffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:DFFN
  • CUSIP: N/A
  • Web: www.diffusionpharma.com
Debt:
  • Current Ratio: 0.60%
  • Quick Ratio: 0.60%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $0.89 per share
  • Price / Book: 1.52
Profitability:
  • Trailing EPS: ($0.59)
  • Net Income: ($18,030,000.00)
  • Return on Equity: -403.38%
  • Return on Assets: 40.33%
Misc:
  • Employees: 10
  • Outstanding Shares: 14,520,000
 

Frequently Asked Questions for RestorGenex Corp. (NASDAQ:DFFN)

What is RestorGenex Corp.'s stock symbol?

RestorGenex Corp. trades on the NASDAQ under the ticker symbol "DFFN."

When will RestorGenex Corp. make its next earnings announcement?

RestorGenex Corp. is scheduled to release their next quarterly earnings announcement on Friday, March, 30th 2018. View Earnings Estimates for RestorGenex Corp..

Who are some of RestorGenex Corp.'s key competitors?

How do I buy RestorGenex Corp. stock?

Shares of RestorGenex Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RestorGenex Corp.'s stock price today?

One share of RestorGenex Corp. stock can currently be purchased for approximately $1.35.

How big of a company is RestorGenex Corp.?

RestorGenex Corp. has a market capitalization of $19.49 million. The company earns ($18,030,000.00) in net income (profit) each year or ($0.59) on an earnings per share basis. RestorGenex Corp. employs 10 workers across the globe.

How can I contact RestorGenex Corp.?

RestorGenex Corp.'s mailing address is 2020 Avon Ct Ste 4, CHARLOTTESVILLE, VA 22902-8734, United States. The company can be reached via phone at +1-434-2200718 or via email at [email protected]


MarketBeat Community Rating for RestorGenex Corp. (NASDAQ DFFN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  18 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  33
MarketBeat's community ratings are surveys of what our community members think about RestorGenex Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for RestorGenex Corp. (NASDAQ:DFFN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for RestorGenex Corp. (NASDAQ:DFFN)

Price Target History for RestorGenex Corp. (NASDAQ:DFFN)

Analysts' Ratings History for RestorGenex Corp. (NASDAQ:DFFN)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for RestorGenex Corp. (NASDAQ:DFFN)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for RestorGenex Corp. (NASDAQ:DFFN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.37)($0.37)($0.37)
Q3 20171($0.43)($0.43)($0.43)
Q4 20171($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RestorGenex Corp. (NASDAQ:DFFN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for RestorGenex Corp. (NASDAQ DFFN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for RestorGenex Corp. (NASDAQ DFFN)

Source:
DateHeadline
DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBMDFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM
finance.yahoo.com - November 16 at 6:27 PM
Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business UpdateDiffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 13 at 12:12 PM
RestorGenex Corp. (DFFN) to Release Quarterly Earnings on MondayRestorGenex Corp. (DFFN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:44 AM
Todays Research Reports on Stocks to Watch: Neothetics, Inc. and Diffusion PharmaceuticalsToday's Research Reports on Stocks to Watch: Neothetics, Inc. and Diffusion Pharmaceuticals
finance.yahoo.com - October 18 at 7:14 PM
Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma MultiformeDiffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme
finance.yahoo.com - October 17 at 6:36 PM
Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35%Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35%
finance.yahoo.com - October 17 at 6:36 PM
Diffusion Pharmaceuticals to Present at the 2017 BIO Investor ForumDiffusion Pharmaceuticals to Present at the 2017 BIO Investor Forum
finance.yahoo.com - October 10 at 3:34 PM
Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)?Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)?
finance.yahoo.com - September 14 at 12:13 AM
DFFN: Phase 3 Trial of TSC in GBM to Initiate Before End of 2017DFFN: Phase 3 Trial of TSC in GBM to Initiate Before End of 2017
finance.yahoo.com - August 31 at 5:44 PM
Diffusion Pharmaceuticals Names William Hornung Chief Business OfficerDiffusion Pharmaceuticals Names William Hornung Chief Business Officer
finance.yahoo.com - August 23 at 8:00 PM
Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business UpdateDiffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 14 at 6:10 PM
RestorGenex Corp. (NASDAQ:DFFN) Scheduled to Post Quarterly Earnings on MondayRestorGenex Corp. (NASDAQ:DFFN) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - August 7 at 10:28 AM
Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain CancerDiffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer
finance.yahoo.com - August 3 at 11:41 AM

Social Media

Financials

Financials are not available for this stock.

Chart

RestorGenex Corp. (NASDAQ DFFN) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.